Patrick J. Crutcher, a director of Jasper Therapeutics, Inc., acquired 888.0000 shares of Non-Voting Convertible Preferred Stock on July 20, 2026 through a private placement under a securities purchase agreement. After stockholder approval, each preferred share will automatically convert into 61 shares of Voting Common Stock, subject to a beneficial ownership cap between 4.9% and 19.9%. Crutcher was also granted stock options for 15000.0000 shares of Voting Common Stock at a $0.7740 exercise price, vesting 25% after one year and monthly over the following 36 months, contingent on continued service.
Patrick J. Crutcher, a director of Jasper Therapeutics, Inc., directly holds 518,331.0000 shares of Voting Common Stock and Non-Voting Convertible Preferred Stock convertible into 463,452.0000 shares of Voting Common Stock. Each preferred share converts into 61 common shares after stockholder approval, subject to a 4.9%-19.9% beneficial ownership cap, and the preferred stock has no expiration date.
Velan Capital Investment Management and affiliated funds disclose beneficial ownership of 3,349,547 Jasper Therapeutics voting common shares, representing about 9.88% of the company, with certain warrants subject to a 9.99% beneficial ownership blocker. Following the Kira Pharmaceuticals merger, Jasper has 33,204,811 shares outstanding, combining 28,009,802 previously outstanding shares and 5,195,009 newly issued merger shares.
Key holders include Velan Master with 3,021,915 shares (including 640,000 from warrants), Velan Horizon with 82,304 shares, and Avego Healthcare Capital with 245,328 shares. Vishal Kapoor directly holds 35,013 shares, largely via options and prior roles. Without the ownership blocker, the group would beneficially own 3,937,975 shares, or 11.4% of Jasper’s equity. The group reports no transactions in the past 60 days, and Kapoor resigned from the board effective at the Kira merger’s closing.
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, making Kira a wholly owned subsidiary. At closing Jasper issued 5,195,009 shares of common stock and 4,644,977 shares of non-voting convertible preferred stock, each preferred share being convertible into 61 common shares, and assumed Kira options and SAFEs. Immediately after the merger and before new financing, former Kira equityholders held about 88.73% of fully diluted common stock and pre-transaction Jasper holders about 11.27%.
Jasper also agreed to a $132 million private placement of roughly 4.7 million preferred shares, after which pre-transaction Jasper holders, former Kira holders and PIPE investors are expected to own 6.68%, 49.86% and 43.46% of fully diluted common stock, assuming full conversion. Legacy Jasper shareholders receive one non-transferable contingent value right per share, tied to a potential $30 million payment if the FDA grants a Priority Review Voucher for briquilimab by December 31, 2028. Kira licensed KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront, up to $108.5 million in development and regulatory milestones, up to $350 million in sales milestones and tiered royalties. Jasper created a new preferred class with protective voting rights, automatic conversion after stockholder approval and beneficial ownership caps, and refreshed leadership by adding director Patrick Crutcher and appointing Matthew Ros as chief operating officer.
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, combining their immunology-focused pipelines into a single company that will continue trading on Nasdaq under the ticker JSPR. Kira contributed complement-therapy assets including KP-104 and KP-701, while Jasper adds briquilimab, an anti-KIT monoclonal antibody.
Alongside the merger, Jasper agreed to sell approximately 4.7 million shares of non-voting convertible preferred stock in a private placement for gross proceeds of about $132 million, with each preferred share convertible into 61 common shares, subject to stockholder approval and beneficial ownership limits. Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront plus potential milestones. Pro forma ownership is expected to be 6.68% for pre-transaction Jasper holders, 49.86% for former Kira equityholders and 43.46% for private placement investors, with about 653.6 million common shares outstanding. Available cash, including the financing and out-licensing proceeds, is expected to fund operations through the second half of 2028 and support multiple clinical milestones.
Jasper Therapeutics, Inc. (JSPR) is reported to have up to 486,933 shares of its voting common stock beneficially owned by entities affiliated with Millennium Management, representing 1.7% of the class as of 06/30/2026.
Integrated Core Strategies (US) LLC reports beneficial ownership of 486,454 shares, while Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 486,933 shares, all with shared and no sole voting or dispositive power. The reporting persons state that the securities are held by entities subject to voting control and investment discretion by Millennium-related managers and that this should not, by itself, be construed as an admission of beneficial ownership. The filing indicates beneficial ownership of 5 percent or less of Jasper’s voting common stock.
Jasper Therapeutics, Inc. is holding its 2026 annual stockholder meeting virtually on July 31, 2026 at 10:00 a.m. Pacific Time. Stockholders of record as of June 5, 2026, when 28,009,802 common shares were outstanding, may vote online or by proxy.
Investors are asked to elect two Class II directors (Judith Shizuru and Tom Wiggans), ratify PricewaterhouseCoopers LLP as the independent auditor for 2026, and approve on an advisory basis executive compensation. The proxy explains voting mechanics, quorum requirements, broker non-votes, and outlines board structure, committee responsibilities, and non-employee director fees and option grants.
Jasper Therapeutics reported receiving a Nasdaq notice that its voting common stock failed to meet the $1.00-per-share minimum bid requirement for the last thirty consecutive business days under Nasdaq Listing Rule 5550(a)(2). Nasdaq has given the company 180 calendar days, until November 30, 2026, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days.
The notice does not immediately affect trading, and the stock and public warrants continue on the Nasdaq Capital Market under “JSPR” and “JSPRW.” If compliance is not restored, Jasper may qualify for an additional 180-day period and is evaluating options, including a potential reverse stock split, but there is no assurance it will meet Nasdaq’s standards.
Jasper Therapeutics, Inc. announced that its Board has begun a comprehensive review of strategic alternatives following an evaluation of current market conditions, with the stated goal of maximizing shareholder value.
Options under consideration include a sale or licensing of assets, collaborations, a sale of the company, a merger or other strategic transaction, or an orderly wind-down of operations. The company plans to keep evaluating cost‑saving measures to preserve cash and to maintain compliance with regulatory and financial reporting requirements. There is no defined timeline for the process, and Jasper does not guarantee that any transaction will be announced or completed.
Jasper Therapeutics, Inc. reported a governance change as director Christian Nolet resigned from the Board of Directors and the Board committees on which he served, effective May 15, 2026. The company stated that his resignation was not due to any disagreement regarding its operations, policies, or practices.
The Board appointed Svetlana Lucas, Ph.D. as a member of the Board’s Audit Committee. The filing also reiterates that Jasper’s voting common stock, with a par value of $0.0001 per share, trades on Nasdaq under the symbol JSPR, and its redeemable warrants trade under JSPRW.